Praxis Precision Medicines Future Growth
Future criteria checks 6/6
Praxis Precision Medicines is forecast to grow earnings and revenue by 71.7% and 64.6% per annum respectively. EPS is expected to grow by 70.4% per annum. Return on equity is forecast to be 23.9% in 3 years.
Key information
71.7%
Earnings growth rate
70.40%
EPS growth rate
| Biotechs earnings growth | 28.8% |
| Revenue growth rate | 64.6% |
| Future return on equity | 23.88% |
| Analyst coverage | Good |
| Last updated | 20 Aug 2026 |
Recent future growth updates
Recent updates
PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts have lifted the fair value estimate for Praxis Precision Medicines to $188 from $162, reflecting higher modeled revenue potential for its late stage epilepsy and essential tremor programs, partially offset by a higher discount rate, slightly lower profit margin assumptions, and a richer future P/E multiple. Analyst Commentary Recent Street research on Praxis Precision Medicines shows a wide spread in price targets and views, with several firms highlighting both upside scenarios around epilepsy and essential tremor assets and execution risks tied to clinical outcomes and commercialization.
PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty
Praxis Precision Medicines enters this Narrative Update with the analyst price target higher in absolute dollar terms, supported by research that reflects revised fair value estimates, updated discount rates, refreshed revenue and margin assumptions, and a lower future P/E multiple in response to recent trial outcomes and pipeline commentary. Analyst Commentary Recent research on Praxis Precision Medicines presents a mixed picture, with several firms adjusting price targets and updating models after clinical readouts and management commentary.Praxis: Commercial Launch Could Smash Expectations (Video)
Summary Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry. The analysis emphasizes valuation implications and the significance of the Ulixa launch for PRAX's investment thesis. Read the full article on Seeking Alpha
PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential
The analyst price target for Praxis Precision Medicines moved from $843 to $1,201, with analysts pointing to potential approvals for ulixacaltamide and relutrigine, along with ongoing interest in the broader late stage pipeline as key reasons for their updated assumptions. Analyst Commentary Recent Street research on Praxis Precision Medicines reflects a wide range of views, but several bullish analysts highlight what they see as meaningful upside tied to the company’s late stage neurology pipeline.PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts now place a $162.00 price target on Praxis Precision Medicines, adjusted from an earlier fair value estimate of about $85.76. This reflects updated views on discount rate, revenue growth potential, profit margins, and future P/E assumptions following recent trial outcomes and broader Street research.PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback
Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking AlphaPraxis Precision Medicines: Multiple Potential Drivers
Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking AlphaPraxis Precision Medicines: Great Price Movement, But Still Not Convinced
Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking AlphaEarnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 1,116 | 210 | 274 | 319 | 17 |
| 12/31/2027 | 348 | -300 | -14 | -148 | 18 |
| 12/31/2026 | 1 | -410 | -441 | -379 | 18 |
| 6/30/2026 | N/A | -339 | -306 | -305 | N/A |
| 3/31/2026 | N/A | -327 | -282 | -282 | N/A |
| 12/31/2025 | N/A | -303 | -249 | -249 | N/A |
| 9/30/2025 | 7 | -273 | -229 | -229 | N/A |
| 6/30/2025 | 8 | -251 | -191 | -191 | N/A |
| 3/31/2025 | 8 | -213 | -164 | -164 | N/A |
| 12/31/2024 | 9 | -183 | -132 | -132 | N/A |
| 9/30/2024 | 2 | -151 | -100 | -99 | N/A |
| 6/30/2024 | 2 | -124 | -95 | -95 | N/A |
| 3/31/2024 | 2 | -125 | -99 | -99 | N/A |
| 12/31/2023 | 2 | -123 | -111 | -111 | N/A |
| 9/30/2023 | 2 | -138 | -116 | -116 | N/A |
| 6/30/2023 | 1 | -157 | -138 | -138 | N/A |
| 3/31/2023 | 1 | -183 | -164 | -164 | N/A |
| 12/31/2022 | N/A | -214 | -185 | -185 | N/A |
| 9/30/2022 | N/A | -231 | -202 | -201 | N/A |
| 6/30/2022 | N/A | -232 | -182 | -180 | N/A |
| 3/31/2022 | N/A | -208 | -154 | -153 | N/A |
| 12/31/2021 | N/A | -167 | -126 | -125 | N/A |
| 9/30/2021 | N/A | -135 | -100 | -100 | N/A |
| 6/30/2021 | N/A | -111 | -90 | -90 | N/A |
| 3/31/2021 | N/A | -88 | -70 | -70 | N/A |
| 12/31/2020 | N/A | -70 | -53 | -53 | N/A |
| 9/30/2020 | N/A | -53 | -42 | -42 | N/A |
| 6/30/2020 | N/A | -44 | -36 | -36 | N/A |
| 3/31/2020 | N/A | -41 | N/A | -34 | N/A |
| 12/31/2019 | N/A | -41 | N/A | -33 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).
Earnings vs Market: PRAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PRAX is expected to become profitable in the next 3 years.
Revenue vs Market: PRAX's revenue (64.6% per year) is forecast to grow faster than the US market (13.5% per year).
High Growth Revenue: PRAX's revenue (64.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRAX's Return on Equity is forecast to be high in 3 years time (23.9%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 21:40 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 29 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |